<DOC>
	<DOCNO>NCT02974179</DOCNO>
	<brief_summary>Subjects AG-CLI-0206 phase 3 study receive AMG0001 eligible AG-CLI-0206-LTFU study</brief_summary>
	<brief_title>A Long Term Follow-up Study AMG0001 Subjects With Critical Limb Ischemia</brief_title>
	<detailed_description>The study design assess long term safety subject treat phase 3 study AMG0001 . A health questionnaire use collect specific information subject every 6 month . Only subject randomize AG-CLI-0206 study receive AMG0001 eligible participate long term follow-up study . Subjects receive placebo eligible participation study .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Subjects treat AMG0001 AGCLI0206 study . Subjects provide consent long term followup study either directly legally authorize representative . Subjects provide release information sponsor . Subjects enrol AGCLI0206 study . Subjects enrol AGCLI0206 treat AMG0001 . Subjects provide consent long term followup study either directly legally authorize representative . Subjects provide release information Sponsor contact directly via phone , email and/or mail .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>